987PTrabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study. (23rd October 2018) - Pignata, S; Scambia, G; Mazzei, T; Arruti Barbia, M; Naglieri, E; de Sande, L M